#United States #New York #Class Action #Levi & Korsinsky #MoonLake Immunotherapeutics

Levi & Korsinsky Alerts MoonLake Investors: Important Class Action Notice

Levi & Korsinsky, LLP has officially notified investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a securities class action lawsuit. This lawsuit aims to recover damages for investors who suffered losses as a result of alleged securities fraud occurring between March 10, 2024, and September 29, 2025. As critical deadlines approach, understanding the timeline and implications of this class action is vital for all involved.

Class Action Overview

The core of the lawsuit revolves around serious accusations that the company misrepresented the overall efficacy and safety of its drug candidate, SLK. Investors are encouraged to consider the allegations which state that the statements made by MoonLake misled them regarding the comparative effectiveness of SLK against existing treatments, particularly BIMZELX. The complaint highlights several breaches of trust, including:
1. Assertions that SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F, yet failing to disclose crucial differences in their medical impacts.
2. Claims that SLK's unique Nanobody structure would provide therapeutic advantages not seen with traditional monoclonal antibodies, which the lawsuit suggests is unsubstantiated.
3. The expectation of enhanced tissue penetration with SLK purportedly leading to improved patient outcomes, something that evidence indicates may not be the case.

Legal Timeline and Deadlines

The deadline for investors to act is December 15, 2025. This date marks the end of the period during which potential lead plaintiffs can file requests to represent the class. Those interested in participating must file necessary documentation with the court by this date, although being named as a lead plaintiff is not a prerequisite for a share in any subsequent recoveries from a successful lawsuit outcome.

Next Steps for Investors

Investors who believe they have been adversely affected during the specified time frame are strongly advised to gather their documentation and circumstances of investment to determine their eligibility for the class action. Levi & Korsinsky is dedicated to assisting individuals through this process, providing insights and guidance on filing requirements.

For those affected, assistance is available at no upfront cost. Levi & Korsinsky offers services without any out-of-pocket charges for participating class members. The goal is to ensure that aggrieved shareholders can seek rightful compensation without financial impediments.

Why Choose Levi & Korsinsky?

With a track record spanning over two decades, Levi & Korsinsky has garnered a reputation as a leading firm in the field of securities litigation. Their expertise is substantiated by a robust history of securing substantial damages for investors and a proven team committed to holding companies accountable for misconduct that harms their shareholders. For seven consecutive years, they have been featured among the top securities litigation firms in the United States by ISS Securities Class Action Services, exemplifying their effectiveness in such legal matters.

Contact Information

For more information on how to proceed or for assistance with the lawsuit process, investors may contact Joseph E. Levi, Esq., or Ed Korsinsky, Esq. through the following:

• - Email: [email protected]
• - Phone: (212) 363-7500
• - Office Address: 33 Whitehall Street, 17th Floor, New York, NY 10004

In summary, the impending lawsuit against MoonLake Immunotherapeutics represents a critical juncture for its investors. Immediate action is encouraged to ensure representation and potential recovery of losses. Taking these steps seriously is paramount as the deadlines approach. Stay informed and proactive to safeguard your interests in this significant legal action.